In approximately 20% of multiple myeloma cases loss-of-function mutations for TRAF2, TRAF3 and cIAP1/2 have been identified in patients, leading to NIK-induced activation of both the canonical and alternative NF-κB pathways to regulate cell growth and survival [20], [21]. This evidence concerns the gene NFKB1 and plasma cell myeloma.